Clinical Trial Update: Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)

View source ↗

Summary

A completed clinical trial evaluated Zemplar capsules (paricalcitol) for the treatment of secondary hyperparathyroidism in chronic kidney disease. The results h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• Zemplar (Paricalcitol)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism | Status: COMPLETED | Results posted: 2014-09-15